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Human kallikreins are a group of serine proteases of high sequence homology
whose genes are grouped as a single cluster at chromosome 19. Although the
physiological roles of kallikreins are generally still unknown, members of the
kallikrein family have been clearly implicated in pathological situations such as
cancer and psoriasis. Human kallikrein 7 (hK7) has been shown to be involved in
pathological keratinization, psoriasis and ovarian cancer. In order to gain insight
into the molecular structure of this protein, hK7 was crystallized after
recombinant production in its folded and active form using a periplasmic
secretion vector in Escherichia coli. The crystals belonged to the rhombohedral
space group H32 and diffracted to 2.8 A˚. The phase problem was solved by
molecular replacement using the mouse kallikrein-related protein neuropsin.
Completion of the model and structure refinement are under way.
1. Introduction
Proteases have been shown to play many essential roles in an
extremely wide variety of physiological functions such as degradation
of the extracellular matrix (Werb, 1997), neural degeneration (Tsirka
et al., 1995) and zymogen activation (Stennicke & Salvesen, 2000).
Among more than 500 proteases contained into the human degra-
dome (Puente et al., 2003), the kallikrein (KLK) gene family displays
the largest contiguous cluster of enzyme-coding genes within the
human genome. This cluster, localized on chromosome 19q13.4
(Yousef, Chang et al., 2000), comprises 15 genes (KLK1–KLK15).
Although KLKs generally share 30–50% sequence similarity at the
nucleotide and amino-acid levels (Diamandis et al., 2000), the so-
called ‘classical kallikreins’ (KLK1, KLK2 and KLK3) are by far the
most homologous, sharing 73–84% nucleotide and 61–77% amino-
acid sequence similarity (Henttu & Vihko, 1989).
The proteins encoded by the KLK genes (hKs) are expressed in the
glandular epithelium of many organs. Kallikreins are synthesized as
zymogens which can be converted to the active protein by protease
digestion (Magklara et al., 2003). Other proteolytic enzymes, either
metalloproteinases or serine proteases, can also activate the hKs
(Takada et al., 1985). Hydrolysis of the propeptide induces confor-
mational changes in both the active site and the substrate-binding
specific pocket of the hKs. The physiological roles of kallikrein are
generally still unknown, except for the cases of the tissue kallikreins
hK1 and hK3 (Bhoola et al., 1992; Lilja, 1985). However, dysregula-
tion of KLK synthesis have been described for both steroid-
dependent (ovarian, breast and testicular carcinomas; Magklara
et al., 2001; Yousef et al., 2002) and nonsteroid-dependent (lung
adenocarcinomas, pancreatic cancer or lymphoblastic leukaemia;
Bhattacharjee et al., 2001; Roman-Gomez et al., 2004) tumours. In
cancer pathophysiology, KLKs seem to at least be involved in
extracellular matrix degradation, angiogenesis, invasion and metas-
tasis (Tschesche et al., 1989; Plendl et al., 2000). Surprisingly, high
levels of kallikrein expression seem to be a positive tumour prognosis
factor in some cases (Borgono & Diamandis, 2004).
Human kallikrein 7 (hK7) was initially cloned from the stratum
corneum of human skin (Hansson et al., 1994). It was classified as a
serine protease (Yousef, Scorilas et al., 2000). Subsequently, hK7
(previously named stratum corneum chymotryptic enzyme; SCCE)
was shown to be involved in pathological keratinization, psoriasis and
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ovarian cancer (Tanimoto et al., 1999; Ekholm & Egelrud, 1999).
Zymogen pro-hK7 (27 525 Da, 253 amino-acid residues; Gene ID
5650) is converted by another kallikrein, hK5 (previously termed
SCTE). This mechanism constitutes the first described kallikrein
activation cascade (Caubet et al., 2004). Recent discoveries clearly
show that domains of the LEKTI protein inhibit the activity of both
hK5 and hK7 in the nanomolar range (Egelrud et al., 2005), which
points towards the existence of a complex physiological regulation
loop in the case of the hK5/hK7 couple.
The crystal structures of several human kallikreins, hK1 (Katz et
al., 1998), hK4 (Debela et al., 2006), hK6 (Bernett et al., 2002) and
pro-hK6 (Gomis-Ruth et al., 2002), have been determined. The
overall fold of the hKs resembles that of the chymotrypsin-like serine
proteases. It consists of two juxtaposed -barrels and two -helices,
with the catalytic active site located between the two -barrels (Katz
et al., 1998; Gomis-Ruth et al., 2002). Three conserved residues,
termed the ‘catalytic triad’ (a histidine, an aspartic acid and a serine),
are the essential components of the catalytic site. A group of 10–12
cysteine residues that form either five (hK1, hK2, hK3 and hK13) or
six (hK4, hK12 and hK15) disulfide bonds are also highly conserved.
Despite these similarities, remarkable sequence differences run
parallel to the respective substrate specificities of the various hKs
(Debela et al., 2006). The crystallization and preliminary X-ray
analysis of recombinant hK7 reported here represents the first step
towards the determination of this enzyme structure. The results
should provide an important insight into the structural basis of the
enzymatic properties of this protein.
2. Materials and methods
2.1. Cloning, expression and purification of hK7
A cDNA coding for the full hK7 (Gene ID 5650) was used as a
template for creating by PCR-amplification the mature hK7 (without
the signal peptide and the propeptide; 24 849 Da, 226 amino-acid
residues) fused to a C-terminal His tag (NDTMKHHHHHH) flanked
by EcoRI and HindIII restriction sites. The amplified PCR product
was inserted into the multicloning site of the secretion expression
vector pRHO (Fernandez-Tornero et al., 2002). All enzymes used for
recombinant DNA techniques were from New England Biolabs and
plasmid DNA-isolation kits were from Roche. At all necessary stages,
DNA sequencing was employed to ascertain the accuracy of the
construction. Escherichia coli strain BL21(DE3)SS (Fernandez-
Tornero et al., 2002) was transformed using the pRHO-hK7-HisTag
vector. Cell cultures for protein expression were carried out at 310 K
in LB medium supplemented with ampicillin. Once the culture
reached an OD600 of 0.7, protein expression was induced by adding
isopropyl -d-thiogalactopyranoside to the culture (to a final
concentration of 1 mM). At this point, the temperature was lowered
to 288 K and the cells were grown for a further 48 h. The supernatant
was collected by centrifugation (5260g, 20 min) and the presence of
hK7 was ascertained by Western blot analysis using an anti-His6
peroxidase-coupled mouse antibody (Roche). N-terminal sequencing
was carried out on a microsequencer (Applied Biosystems 494) to
confirm the identity of the protein detected by Western blot analysis.
For purification, the supernatant was directly batch-incubated over-
night at 277 K with SP Sepharose Fast Flow (General Electric) at pH
8.5 and hK7 was eluted from the slurry using a linear 0–1M NaCl
gradient in 50 mM sodium phosphate buffer pH 8.0 after packing the
slurry into a chromatography column. hK7-containing fractions
identified by Western blotting were pooled and applied onto a
column containing 15 ml nickel-chelating Sepharose equilibrated in
the same buffer containing 40 mM imidazole to avoid nonspecific
protein binding. The protein was eluted with a linear 40–500 mM
imidazole gradient in the same buffer. The final purification step was
carried out using a reversed-phase column (Source 15RPC; Phar-
macia) using an acetonitrile gradient in aqueous 0.1% trifluoroacetic
acid. hK7 eluted from this last column in an almost single peak and
was extensively dialyzed against 50 mM sodium phosphate pH 7.5
and lyophilized until future use. Protein purity was assessed at this
stage by Coomassie blue-stained SDS–PAGE (Fig. 1a). The activity of
the recombinant enzyme was assayed using the fluorogenic peptide
Mca-R-P-K-P-V-E-Nval-W-R-K(Dnp)-NH2 (R&D Systems). The
homogeneity of hK7 in solution was determined by dynamic light-
scattering (DLS) measurements in a DynaPro instrument (Protein
Solutions Ltd) with protein concentrations in the range 0.5–
1 mg ml1.
2.2. Crystallization, data collection and processing
Crystallization experiments were carried out at 295 K using the
sitting-drop vapour-diffusion method in 96-well Greiner plates with a
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Figure 1
(a) SDS–PAGE of the final hK7 preparation before setting up crystallization trials.
(b) Optimized rhombohedral crystal of recombinant hK7 obtained using the
sitting-drop vapour-diffusion method. (c) Representative diffraction pattern of hK7
obtained using synchrotron radiation, showing a maximum resolution of 2.8 A˚.
variety of commercially available screens (Hampton Research, Jena
Bioscience and Nextal). The initial hK7 protein concentration was
8 mg ml1 in 50 mM sodium phosphate pH 7.5. Nanodrops were
prepared using a Honeybee X8 Cartesian crystallization robot by
mixing 0.1 ml protein solution with 0.1 ml crystallization buffer.
Several conditions gave small crystals in the initial screens that were
subsequently improved by refining these conditions and adapting
them to standard drops (1 ml). Crystals suitable for diffraction
experiments were transferred from the crystallization drop into a
cryoprotectant solution using nylon loops and were rapidly flash-
cooled to 100 K in liquid nitrogen. The cryoprotectant solution
consisted of the crystallization solution supplemented with 25%(v/v)
glycerol in place of an equivalent volume of buffer. For data collec-
tion, a single crystal was analysed using the synchrotron-radiation
source at the ESRF (Grenoble, France). A complete data set was
collected using a Quantum ADSC detector in 100 frames with an
oscillation range of 1 to a maximum resolution of 2.8 A˚. The
diffraction data were integrated using MOSFLM (Leslie, 2006) and
scaled using SCALA (Evans, 2006). Further analyses were performed
using programs from the CCP4 suite (Collaborative Computational
Project, Number 4, 1994).
3. Results and discussion
We have expressed and purified mature human kallikrein 7 (hK7) in
E. coli cultures using the pRHO T7-secretion vector (Fernandez-
Tornero et al., 2002). The protein-purification protocol from the
supernatant rendered an active hK7 preparation that showed up a
single band on SDS–PAGE (Fig. 1a), corresponding to an unglyco-
sylated polypeptide of 27 kDa (the exact molecular weight of hK7
calculated from the gene sequence is 25 596 Da). The final yield was
0.2 mg purified protein per litre of culture. This is the first time that a
human kallikrein, either as zymogen or mature protein, has been
expressed properly folded in its active form in E. coli.
Crystals of recombinant hK7 were grown at pH 7.5 by the sitting-
drop vapour-diffusion method from several different crystallization
conditions that contained ammonium sulfate as the main precipitant.
Improved crystals were subsequently obtained with a precipitant
solution consisting of 3.2M ammonium sulfate in 0.1M HEPES pH
7.0. Crystallization was reproducible under these conditions, with
crystals of maximum dimensions 50  50  100 mm appearing after
one month (Fig. 1b). X-ray data were collected from a single crystal at
100 K at the European Synchrotron Radiation Facility to a maximum
resolution of 2.8 A˚ (Fig. 1c). Crystals belong to the rhombohedral
space group H32, with unit-cell parameters a = b = 113.6, c = 326.4 A˚
(hexagonal setting). Data-collection statistics are summarized in
Table 1. Estimation of the protein content using the Matthews
coefficient calculation (Matthews, 1968) suggested that two or three
hK7 subunits were most likely to be present, giving solvent contents
of 68.8% or 53.2% and VM values of 4.0 or 2.6 A˚
3 Da1, respectively.
A self-rotation function using MOLREP (Vagin & Teplyakov, 1997)
did not show any significant noncrystallographic axes (twofold or
threefold axes), perhaps owing to their relative parallel (or close to
parellel) orientation to the crystallographic axes. Structure elucida-
tion of hK7 will provide important clues towards understanding the
enzymatic properties of this protein.
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Data-collection and processing statistics.
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